Article Excerpt: It doesn’t get that much attention, but the methamphetamine epidemic in the U.S. is startlingly widespread and lethal… At the same time, effective treatment often relies on behavioral therapy programs that aren’t tailored to the needs of meth addicts, according to Kristin Muhlner, CEO and co-founder of addiction treatment startup Affect Therapeutics. There is no FDA-approved medical therapy for methamphetamine user disorder. That’s why in 2020, Muhlner joined forces with Dr. Jeff De Flavio, a founder of opioid addiction treatment programs, among other ventures aimed at broadening access to healthcare, to launch Affect, a New York City startup with an app-based treatment program for meth addicts that combines reward systems—paying cash for achieving certain tasks—with group therapy.
Full Article: https://tinyurl.com/4k4ennf5
Article Source: Forbes